CytomX Therapeutics is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.18 – an increase of 5.36% over the previous week. CytomX Therapeutics employs 120 staff and has a trailing 12-month revenue of around $119.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.18 |
|---|---|
| 52-week range | $1.04 - $5.85 |
| 50-day moving average | $1.19 |
| 200-day moving average | $1.67 |
| Wall St. target price | $5.31 |
| PE ratio | 7.4667 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.15 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.09 from 2024-10-14
| 1 week (2024-10-10) | -2.68% |
|---|---|
| 1 month (2024-09-17) | -9.92% |
| 3 months (2024-07-17) | -24.31% |
| 6 months (2024-04-17) | -38.07% |
| 1 year (2023-10-17) | -19.26% |
|---|---|
| 2 years (2022-10-17) | -22.70% |
| 3 years (2021-10-15) | 5.14 |
| 5 years (2019-10-17) | 7.12 |
Valuing CytomX Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CytomX Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CytomX Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, CytomX Therapeutics shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
CytomX Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.6 million.
The EBITDA is a measure of a CytomX Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $119.6 million |
|---|---|
| Gross profit TTM | $53.2 million |
| Return on assets TTM | 1.94% |
| Return on equity TTM | -5475.03% |
| Profit margin | 9.27% |
| Book value | $-0.40 |
| Market Capitalization | $87.5 million |
TTM: trailing 12 months
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $1.04 up to $5.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 1.035. This would suggest that CytomX Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
CytomX Therapeutics, Inc. , an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.